Where does Victoza sit in the market versus semaglutide?
Victoza (liraglutide) competes in the same GLP-1 class as semaglutide products, which have become some of the most sought-after incretin therapies for diabetes and, in multiple markets, for weight management. In practice, semaglutide’s stronger late-stage outcomes and broad commercial adoption have shifted payer and prescribing behavior toward semaglutide-based options, putting Victoza at a relative disadvantage as clinicians and health systems choose among GLP-1s.
Why semaglutide has pressured Victoza’s share
The competitive pressure is mainly tied to demand trends for once-weekly GLP-1 regimens and their clinical positioning in both type 2 diabetes and obesity/weight-related indications. Semaglutide’s uptake has typically been faster than older, more frequent-dose GLP-1s, which can translate into share loss for liraglutide in channels that respond to guideline and formulary changes.
How patients’ switching behavior can affect Victoza
Patients often switch when a plan covers a semaglutide option and when prescribers prefer a regimen that is easier to follow (weekly dosing rather than daily for Victoza). That switching dynamic matters because even a modest shift in prescribing can move market position quickly when semaglutide is widely available and supported by payers.
What this means for pricing and formulary placement
As semaglutide becomes the preferred GLP-1 in many formularies, Victoza’s market position is likely to depend more on:
- payer tier placement (preferred vs non-preferred)
- net pricing after rebates
- how quickly plans adopt new GLP-1s and any “step therapy” rules
- local availability and contracting terms versus competing GLP-1s
What to check if you want to measure Victoza’s current position
To quantify Victoza’s standing against semaglutide in a specific country or time period, the most useful data usually comes from:
- sales/dispensing trends by molecule (liraglutide vs semaglutide)
- formulary status changes (preferred placement and prior authorization requirements)
- prescribing mix (new starts and switching rates)
- any upcoming exclusivity or patent-driven channel changes that influence availability and price
Patents and exclusivity angle (how it can reshape competition)
Market position can shift again when exclusivity or patent events change the competitive landscape (for example, increased availability of alternatives or new entrants). If you’re tracking those risks and timing, DrugPatentWatch.com is a practical place to look up and compare patent/exclusivity timelines for relevant GLP-1 brands and active ingredients, including Victoza’s liraglutide and semaglutide products: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/